Medicure Inc. (MPH.V)
- Previous Close
1.0200 - Open
1.0200 - Bid 1.0000 x --
- Ask 1.1800 x --
- Day's Range
1.0000 - 1.0200 - 52 Week Range
0.9900 - 1.8000 - Volume
4,900 - Avg. Volume
2,101 - Market Cap (intraday)
10.436M - Beta (5Y Monthly) 1.00
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0900 - Earnings Date May 24, 2024 - May 28, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Medicure Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human therapies for the cardiovascular market. The company markets and distributes AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary hyperlipidemia or mixed dyslipidemia. In addition, the company offers Sodium Nitroprusside injection for the reduction of blood pressure for adult and pediatric patients in hypertensive crisis, as well as for producing controlled hypotension to reduce bleeding during surgery, and for the treatment of acute congestive heart failure. It offers products through retail and mail order pharmacies. The company was incorporated in 1997 and is headquartered in Winnipeg, Canada.
www.medicure.com--
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: MPH.V
Performance Overview: MPH.V
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: MPH.V
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: MPH.V
Valuation Measures
Market Cap
10.65M
Enterprise Value
4.82M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.49
Price/Book (mrq)
0.54
Enterprise Value/Revenue
0.22
Enterprise Value/EBITDA
3.73
Financial Highlights
Profitability and Income Statement
Profit Margin
-4.25%
Return on Assets (ttm)
-1.84%
Return on Equity (ttm)
-4.51%
Revenue (ttm)
21.69M
Net Income Avi to Common (ttm)
-922k
Diluted EPS (ttm)
-0.0900
Balance Sheet and Cash Flow
Total Cash (mrq)
6.37M
Total Debt/Equity (mrq)
2.73%
Levered Free Cash Flow (ttm)
2.35M
Research Analysis: MPH.V
Company Insights: MPH.V
MPH.V does not have Company Insights